201 related articles for article (PubMed ID: 37786901)
41. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
42. Influencing factors of anti-SARS-CoV-2-spike-IgG antibody titers in healthcare workers: A cross-section study.
Reusch J; Wagenhäuser I; Gabel A; Eggestein A; Höhn A; Lâm TT; Frey A; Schubert-Unkmeir A; Dölken L; Frantz S; Kurzai O; Vogel U; Krone M; Petri N
J Med Virol; 2023 Jan; 95(1):e28300. PubMed ID: 36369641
[TBL] [Abstract][Full Text] [Related]
43. Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study.
Mishra SK; Pradhan SK; Pati S; Sahu S; Nanda RK
Cureus; 2021 Nov; 13(11):e19879. PubMed ID: 34976499
[TBL] [Abstract][Full Text] [Related]
44. Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R; Harada M; Yamada A; Aomura D; Yamada Y; Sonoda K; Nakazawa H; Sakai K; Mizukami E; Hashimoto K; Kamijo Y
Clin Exp Nephrol; 2023 Aug; 27(8):660-671. PubMed ID: 37095343
[TBL] [Abstract][Full Text] [Related]
45. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC
J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651
[TBL] [Abstract][Full Text] [Related]
46. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
47. [Survey of spike-specific immunoglobulin G antibodies at approximately 3 months and 9 months after vaccination against coronavirus disease 2019 (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) in health care workers].
Miyajima E; Imaizumi H; Oshida S; Igarashi K; Yoshida M; Yanase N
Sangyo Eiseigaku Zasshi; 2023 Jan; 65(1):18-27. PubMed ID: 35314567
[TBL] [Abstract][Full Text] [Related]
48. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
49. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
50. SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses.
Montez-Rath ME; Garcia P; Han J; Cadden L; Hunsader P; Morgan C; Kerschmann R; Beyer P; Dittrich M; Block GA; Anand S; Parsonnet J; Chertow GM
medRxiv; 2022 Mar; ():. PubMed ID: 35313586
[TBL] [Abstract][Full Text] [Related]
51. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
52. A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients.
Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
Ups J Med Sci; 2022; 127():. PubMed ID: 36337280
[TBL] [Abstract][Full Text] [Related]
53. Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients.
Balčiuvienė V; Burčiuvienė A; Haarhaus M; Uogintaitė J; Janavičienė A; Santockienė L; Mitrikevičienė J; Aleknienė L; Keinaitė D
Acta Med Litu; 2023; 30(1):26-38. PubMed ID: 37575375
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
[TBL] [Abstract][Full Text] [Related]
55. Humoral immunity trends in a hemodialysis cohort following SARS-CoV-2 mRNA booster: A cohort study.
Goggins E; Sharma B; Ma JZ; Gautam J; Bowman B
Health Sci Rep; 2024 Feb; 7(2):e1858. PubMed ID: 38357484
[TBL] [Abstract][Full Text] [Related]
56. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
[TBL] [Abstract][Full Text] [Related]
57. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
58. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
59. Quantitative Analysis of SARS-CoV-2 Serological Responses Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Gong CY; Sheth P; Martinez-Cajas J; Gong Y
Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298455
[TBL] [Abstract][Full Text] [Related]
60. Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.
Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Garza-Herrera MR; Leal-Meléndez JA; Sanz-Sánchez MÁ
PLoS One; 2022; 17(3):e0263942. PubMed ID: 35235587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
